Skip to main content

Table 1 Comparison of patient characteristics between those taking and not taking NSBB at the initial visit for liver transplant evaluation. Values are shown as median (interquartile range) or number (percentage)

From: Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation

 

On NSBB

n = 65

Not on NSBB

n = 105

P value

Age, years

58 (52–64)

59 (53–63)

NS

BMI

28 (25–35)

29 (25–35)

NS

Male gender

43 (66%)

64 (64%)

NS

Diabetes mellitus

21 (32%)

33 (32%)

NS

Hypertension

28 (43%)

52 (50%)

NS

Chronic kidney disease

16 (25%)

11 (11%)

.02

Heart rate beats/min

66 (60–73)

78 (70–88)

<.001

Mean arterial pressure, mmHg

82 (76–93)

86 (78–93)

NS

Race

 Caucasian

57 (88%)

91 (87%)

NS

 Black

3 (5%)

7 (7%)

 Hispanic

4 (6%)

5 (5%)

 Other

1 (1%)

2 (2%)

Cirrhosis Etiology

 Hepatitis C

27 (42%)

57 (54%)

NS

 Alcohol

23 (34%)

31 (30%)

NS

 NASH

20 (30%)

22 (21%)

NS

Child Pugh Score

10 (9–11)

9 (7–10)

.001

Child Pugh class

 A

3 (5%)

16 (15%)

.01

 B

24 (37%)

50 (48%)

 C

38 (58%)

39 (38%)

MELD

16 (14–19)

14 (10–19)

0.03

INR

1.5 (1.3–1.7)

1.3 (1.2–1.6)

.04

Bilirubin mg/dL

2.7 (2–3.7)

1.9 (1.3–3.5)

.04

Creatinine mg/dL

1.1 (0.8–1.4)

0.9 (0.7–1.2)

.1

Albumin g/dL

2.9 (2.5–3.1)

3 (2.5–3.4)

NS

Sodium

135 (132–137)

135 (131–138)

NS

Esophageal varices

 None or small

24 (37%)

70 (71%)

<.001

 Non-bleeding large

21 (32%)

19 (19%)

 Prior bleeding

20 (31%)

13 (13%)

Gastric varices

 None or small

61 (94%)

100 (98%)

NS

 Non-bleeding large

2 (3%)

None

 Prior bleeding

2 (3%)

2 (2%)

Ascites

 None

12 (18%)

30 (30%)

NS

 Controlled

35 (55%)

53 (51%)

 Refractory

18 (27%)

21 (20%)

Hepatic encephalopathy

 None

18 (28%)

41 (40%)

NS

 Controlled

32 (48%)

48 (47%)

 Refractory

15 (24%)

14 (13%)

Transjugular Intrahepatic Portosystemic shunt

5 (8%)

13 (13%)

NS

Cirrhosis complications

 Spontaneous bacterial peritonitis

2 (3%)

3 (3%)

NS

 Hepatorenal syndrome

2 (3%)

3 (3%)

NS

 Hepatopulmonary syndrome

None

2 (2%)

NS

 Portopulmonary hypertension

2 (3%)

5 (5%)

NS

 Hepatocellular carcinoma

10 (15%)

26 (26%)

NS

Acute kidney injury associated with hospitalization prior to liver transplant evaluation

7 (11%)

13 (13%)

NS

NSBB indication

 Large or previously bleeding varices

42 (65%)

34 (32%)

<.001

NSBB contraindication (refractory ascites or spontaneous bacterial peritonitis)

20 (31%)

24 (23%)

NS

  1. Abbreviations: BP blood pressure, MELD model for end-stage liver disease, NSBB non-selective beta blockers, NS not significant